随机试验报道,在怀孕期间补充n-3长链多不饱和脂肪酸(LCPUFA)可以延长怀孕时间,从而增加出生体重。
我们旨在研究妊娠期补充n-3LCPUFA与妊娠持续时间的关系,出生体重,和胎龄大小(GA)。
这是一项针对736名孕妇及其后代的双盲随机对照试验。来自2010年儿童哮喘的哥本哈根前瞻性研究。他们在怀孕22至26周之间招募,每天随机分配到2.4gn-3LCPUFA或对照(橄榄油),直到出生后1周。排除标准是内分泌,心血管,或肾病和维生素D补充摄入量>600IU/d。在这项研究中,我们分析了次要结果,并进一步排除双胎妊娠和宫外死亡。该试验的主要结果是持续性喘息或哮喘。
随机分配在2008年至2010年之间进行。分析中包括69对母婴对。与对照组相比,n-3LCPUFA与妊娠2d延长相关[中位数(IQR):282(275-288)d与280(273-286)d相比,P=0.02],出生体重高97克(平均±SD:3601±534克,与3504±528克相比,P=0.02),根据挪威基于人口的生长曲线,GA的大小增加了-Skjärven(平均值±SD:49.9±28.3百分位数与44.5±27.6百分位数相比,P=0.01)。
在妊娠晚期补充n-3LCPUFA的孕妇与妊娠时间延长和GA增大有关,在这项随机对照试验中导致更高的出生体重。该试验在clinicaltrials.gov注册为NCT00798226。
Randomized trials have reported that supplementation with n-3 long-chain polyunsaturated fatty acids (LCPUFAs) in pregnancy can prolong pregnancy and thereby increase birth weight.
We aimed to examine the relations of n-3 LCPUFA supplementation in pregnancy with duration of pregnancy, birth weight, and size for gestational age (GA).
This was a double-blind randomized controlled trial conducted in 736 pregnant women and their offspring, from the Copenhagen Prospective Studies on Asthma in Childhood2010cohort. They were recruited between weeks 22 and 26 in pregnancy and randomly assigned to either of 2.4 g n-3 LCPUFA or control (olive oil) daily until 1 wk after birth. Exclusion criteria were endocrine, cardiovascular, or nephrologic disorders and vitamin D supplementation intake >600 IU/d. In this study we analyzed secondary outcomes, and further excluded twin pregnancies and extrauterine death. The primary outcome for the trial was persistent wheeze or asthma.
The random assignment ran between 2008 and 2010. Six hundred and ninety-nine mother-infant pairs were included in the analysis. n-3 LCPUFA compared with control was associated with a 2-d prolongation of pregnancy [median (IQR): 282 (275-288) d compared with 280 (273-286) d, P = 0.02], a 97-g higher birth weight (mean ± SD: 3601 ± 534 g compared with 3504 ± 528 g, P = 0.02), and an increased size for GA according to the Norwegian population-based growth curves-Skjærven (mean ± SD: 49.9 ± 28.3 percentiles compared with 44.5 ± 27.6 percentiles, P = 0.01).
Supplementing pregnant women with n-3 LCPUFAs during the third trimester is associated with prolonged gestation and increased size for GA, leading to a higher birth weight in this randomized controlled trial. This trial was registered at clinicaltrials.gov as NCT00798226.